Accolade, Inc. (NASDAQ:ACCD) Short Interest Update

Accolade, Inc. (NASDAQ:ACCD - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,430,000 shares, an increase of 10.3% from the December 31st total of 3,110,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the short-interest ratio is currently 1.9 days.

Insider Transactions at Accolade

In related news, CEO Rajeev Singh sold 13,357 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total transaction of $48,085.20. Following the completion of the sale, the chief executive officer now directly owns 814,316 shares in the company, valued at approximately $2,931,537.60. The trade was a 1.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 41,947 shares of company stock worth $154,439 in the last ninety days. Insiders own 8.20% of the company's stock.

Institutional Investors Weigh In On Accolade

A number of large investors have recently modified their holdings of ACCD. Mission Creek Capital Partners Inc. acquired a new stake in Accolade in the 3rd quarter worth approximately $38,000. Pallas Capital Advisors LLC acquired a new stake in shares of Accolade during the fourth quarter worth $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of Accolade during the third quarter valued at $46,000. Wolverine Trading LLC purchased a new stake in shares of Accolade during the third quarter valued at $51,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its position in shares of Accolade by 1,144.1% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company's stock valued at $81,000 after acquiring an additional 19,232 shares during the period. Hedge funds and other institutional investors own 84.99% of the company's stock.

Accolade Stock Up 0.1 %

NASDAQ:ACCD opened at $6.89 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. The stock has a market capitalization of $562.16 million, a P/E ratio of -3.06 and a beta of 2.08. The company's 50-day simple moving average is $4.68 and its 200-day simple moving average is $4.11. Accolade has a fifty-two week low of $3.08 and a fifty-two week high of $13.93.

Accolade (NASDAQ:ACCD - Get Free Report) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, equities analysts anticipate that Accolade will post -1.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ACCD shares. Truist Financial lowered Accolade from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 10th. William Blair cut Accolade from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, January 8th. Morgan Stanley lowered their price objective on Accolade from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Tuesday, December 17th. Canaccord Genuity Group reissued a "hold" rating on shares of Accolade in a report on Wednesday, January 8th. Finally, Barclays decreased their target price on shares of Accolade from $5.50 to $5.00 and set an "equal weight" rating on the stock in a research note on Wednesday, October 9th. Twelve analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Accolade has an average rating of "Hold" and a consensus price target of $7.55.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.